Isolating immune cells from a patient and developing an autologous CAR T therapy is a complex process that involves multiple steps, instruments, and reagents. Open processing and manual handling during CAR T cell manufacturing leads to errors and contamination. A modular, semiautomatic, and closed system reduces variables and relieves CAR T bioprocessing bottlenecks. 

Download this white paper from Thermo Fisher Scientific to learn how to achieve efficient and reliable CAR T cell therapy manufacturing from start to finish.  

Sponsored by